Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer

被引:25
|
作者
Liu, Jen-Jane [1 ]
Lichtensztajn, Daphne Y. [2 ]
Gomez, Scarlett Lin [2 ]
Sieh, Weiva [3 ]
Chung, Benjamin I. [1 ]
Cheng, Iona [2 ]
Brooks, James D. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA
[2] Canc Prevent Inst Calif, Fremont, CA USA
[3] Stanford Univ, Sch Med, Div Epidemiol, Dept Hlth Res & Policy, Stanford, CA 94305 USA
关键词
SEER Program; prostatic neoplasms; lymph node metastasis; Gleason score; ACTIVE SURVEILLANCE; REPRODUCIBILITY; ADENOCARCINOMA; CARCINOMA; IMPACT; GRADE;
D O I
10.1097/PAT.0000000000000097
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3 + 3 = 6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer. We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and >= 1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48%. Older age, preoperative PSA >10 ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.
引用
收藏
页码:306 / 310
页数:5
相关论文
共 50 条
  • [31] Definition of Insignificant Tumor Volume of Gleason Score 3+3=6 (Grade Group 1) Prostate Cancer at Radical Prostatectomy-Is it Time to Increase the Threshold?
    Kryvenko, Oleksandr N.
    Epstein, Jonathan I.
    JOURNAL OF UROLOGY, 2016, 196 (06): : 1664 - 1668
  • [32] Gleason 3+3=6 and Intraductal Carcinoma (IDC-P) on Prostate Biopsy Specimens
    Khani, Francesca
    Epstein, Jonathan
    LABORATORY INVESTIGATION, 2015, 95 : 234A - 234A
  • [33] Gleason 3+3=6 and Intraductal Carcinoma (IDC-P) on Prostate Biopsy Specimens
    Khani, Francesca
    Epstein, Jonathan
    MODERN PATHOLOGY, 2015, 28 : 234A - 234A
  • [34] The origin of lymph node metastases in prostate cancer
    Hong, Matthew
    Chung, Jessica
    Macintyre, Geoff
    Chin, Xiaowen
    Pedersen, John
    Costello, Anthony
    Hovens, Christopher
    Corcoran, Niall
    BJU INTERNATIONAL, 2013, 112 : 52 - 52
  • [35] Favorable Gleason 3+4 Prostate Cancer Shows Comparable Outcomes With Gleason 3+3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance
    Lee, Hakmin
    Lee, In Jae
    Byun, Seok-Soo
    Lee, Sang Eun
    Hong, Sung Kyu
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E1117 - E1122
  • [36] Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance?
    Ghiasy, Saleh
    Abedi, Amir Reza
    Moradi, Afshin
    Hosseini, Seyed Yousef
    Karkan, Morteza Fallah
    Sadri, Ghazal
    Davari, Mohammadreza
    TURKISH JOURNAL OF UROLOGY, 2019, 45 (04): : 261 - 264
  • [37] African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance
    Kryvenko, Oleksandr N.
    Balise, Raymond
    Prakash, Nachiketh Soodana
    Epstein, Jonathan I.
    JOURNAL OF UROLOGY, 2016, 195 (02): : 301 - 306
  • [38] Gleason score 3+3[6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients
    Samaratunga, Hemamali
    Egevad, Lars
    Yaxley, John
    Perry-Keene, Joanna
    Le Fevre, Ian
    Kench, James
    Matsika, Admire
    Bostwick, David
    Iczkowski, Kenneth
    Delahunt, Brett
    PATHOLOGY, 2024, 56 (01) : 33 - 38
  • [39] DNA copy number and DNA methylome analysis of primary prostate cancer and pathologic lymph node metastases in patients with low and high Gleason score
    Schmidt-Hegemann, N. -S
    Hess-Rieger, J.
    Unger, K.
    Link, V
    Buchner, A.
    Eze, C.
    Li, M.
    Stief, C.
    Kirchner, T.
    Ganswindt, U.
    Zitzelsberger, H.
    Belka, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S158 - S159